Acción 603739 QINGDAO VLAND BIOTECH INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Qingdao Vland Biotech INC.

Acciones

603739

CNE100003GX8

Precio de cierre Shanghai S.E.
Otros sitios de cotización
 00:00:00 13/05/2024 		Varia. Cinco días. Varia. 1 de enero.
19,4 CNY -4,90 % Gráfico intradía de Qingdao Vland Biotech INC. +27,13 % +27,46 %
07/05 Las bolsas chinas bajan; las acciones de Hong Kong caen tras 10 días de racha ganadora RE
25/04 Qingdao Vland Biotech INC. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
China stocks edge down; HK shares fall after 10-day winning streak
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 603739
  4. Noticias Qingdao Vland Biotech INC.
  5. Otros idiomas